$CAPR News

Activist Investor Sounds Alarm on Capricor’s Cash Burn

Kaos Capital Plans To Nominate Two Independent Directors On Capricor Therapeutics' Board; To Seek Board-Led M&A, Strategic Alternatives Committee

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom

Capricor Therapeutics (CAPR) Faces Class Action Scrutiny, Is The 88% Undervalued Case Credible?

Capricor Therapeutics (CAPR) Is Up 62.6% After Mounting Deramiocel FDA Scrutiny And Lawsuits - What's Changed

Capricor: Stock Now Surging On Fresh BLA Updates - What Investors Must Know

CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval

Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and ...

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

CAPR Stock Surges 67% After-Hours — Is There Still A Path Forward For Deramiocel?

Capricor Therapeutics Q2 Earnings Call Highlights

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics, Inc. (CAPR) Q2 2026 Earnings Call Prepared Remarks Transcript

Capricor Therapeutics Q2 2026 Earnings Call Transcript

Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate

Capricor Therapeutics (CAPR) Stock Fair Value Falls After Deramiocel AdCom Setback

CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy